Inno-lipa HPV genotyping extra

Inno-lipa HPV genotyping extra has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Nov 16, 2026: “Comparative performance of three HPV DNA detection assays for cervical cancer screening in Algeria”.

Exposure

1 paper studies it2 findingsUpdated

1 new paper in 30 daysSee all 1 papers on inno-lipa HPV genotyping extra

At a glance

The findings reach people, from one lab or study. 1 lab.

“Among the 94 specimens tested by both INNO-LiPA and Cobas, HR-HPV was detected in 54.3% and 29.8%, respectively”
Comparative performance of three HPV DNA detection assays for cervical cancer screening in AlgeriaAfrican journal of reproductive health2026doi:10.29063/ajrh2026/v30i21.10

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab
  • Humans1

What did studies of inno-lipa HPV genotyping extra find?

1

Studies of inno-lipa HPV genotyping extra measured one outcome, high-risk HPV detection.

High-risk HPV detection

upin humans1

1 study
  1. Inno-lipa HPV genotyping extra is linked with higher high-risk HPV detection in humans (Compared with Cobas 4800 HPV) (54.3% versus 29.8%).

    “Among the 94 specimens tested by both INNO-LiPA and Cobas, HR-HPV was detected in 54.3% and 29.8%, respectively”

    HumansCompared with Cobas 4800 HPVcervixfemalesn = 94

    Comparative performance of three HPV DNA detection assays for cervical cancer screening in Algeria

    African journal of reproductive health

More on High-risk HPV detection

What is inno-lipa HPV genotyping extra linked with?

1

Studies link inno-lipa HPV genotyping extra with Diagnostic sensitivity and specificity.

Diagnostic sensitivity and specificity

mixedin humans1

1 study
  1. Inno-lipa HPV genotyping extra is associated with diagnostic sensitivity and specificity in humans (Compared with Cobas using the study-defined composite reference classification) (Sensitivity 93% versus 71%; specificity 62% versus 88%).

    “INNO-LiPA showed higher sensitivity (93%) but lower specificity (62%) than Cobas (71% and 88%, respectively).”

    HumansCompared with Cobas using the study-defined composite reference classificationcervixfemales

    Comparative performance of three HPV DNA detection assays for cervical cancer screening in Algeria

    African journal of reproductive health

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 11 paper in 12 months